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Michael J. Borowitz,4 Peter Dreger,5 Issa Khouri,6 Homer Macapintac,7 Eduardo Olavarria,8
Jerald Radich,9 Wendy Stock,10 Julie M. Vose,11 Daniel Weisdorf,12 Andre Willasch,2
Sergio Giralt,6 Michael R. Bishop,13 Alan S. Wayne14Relapse has become the major cause of treatment failure after allogeneic stem cell transplantation. Outcome
of patients with clinical relapse after transplantation generally remains poor, but intervention prior to florid
relapse improves outcome for certain hematologic malignancies. To detect early relapse or minimal residual
disease, sensitive methods such as molecular genetics, tumor-specific molecular primers, fluorescein in situ
hybridization, andmultiparameter flow cytometry (MFC) are commonly used after allogeneic stem cell trans-
plantation to monitor patients, but not all of them are included in the commonly employed disease-specific
response criteria. The highest sensitivity and specificity can be achieved bymolecular monitoring of tumor- or
patient-specific markers measured by polymerase chain reaction-based techniques, but not all diseases have
such targets for monitoring. Similar high sensitivity can be achieved by determination of donor chimerism, but
its specificity regarding detection of relapse is low and differs substantially among diseases. Here, we summa-
rize the current knowledge about the utilization of such sensitive monitoring techniques based on tumor-
specific markers and donor cell chimerism and how these methods might augment the standard definitions
of posttransplant remission, persistence, progression, relapse, and the prediction of relapse. Critically impor-
tant is the need for standardization of the different residual disease techniques and to assess the clinical
relevance of minimal residual disease and chimerism surveillance in individual diseases, which in turn, must
be followed by studies to assess the potential impact of specific interventional strategies.
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Methodologic and technologic advances allow
sensitive detection of minimal residual disease
(MRD) and early recognition of recurrence of hema-
tologic malignancies after allogeneic hematopoietic
stem cell transplantation (alloHSCT). Importantly,
intervention prior to florid relapse improves outcome
for certain hematologic malignancies [1,2]. This
manuscript by the Workshop Committee on Disease-
Specific Methods and Strategies for Monitoring Relapse fol-
lowing Allogeneic Stem Cell Transplantation is divided
into 2 parts and reviews disease-specific detection
methods and available data with the use of such after
alloHSCT. Given the critical importance to the goals
of this Workshop, standard disease-specific response
and relapse criteria are summarized. Outside of the al-
loHSCT setting, international working groups have
developed standard diagnostic criteria that are widely
employed in the definition of relapse for the different
hematologic malignancies [3]. These are based on
morphologic investigations of peripheral blood (PB)
and/or bone marrow (BM), imaging, and/or specific
laboratory findings. Given their critical importance
to the goals of this Workshop, these criteria are summa-
rized here. However, after alloHSCT, more sensitive
methods such as molecular genetics, tumor-specific
molecular primers, fluorescein in situ hybridization
(FISH), multiparameter flow cytometry (MFC), and/
or chimerism are commonly used to monitor patients
with respect to relapse. Although some of these have
clearly been shown to be predictive of outcome in spe-
cific diseases (eg, chronic myelogenous leukemia
[CML]), and have become part of the standard criteria,
assays for monitoring of disease status after alloHSCT
have not yet been incorporated into the relapse defini-
tions across all hematologic malignancies. Recom-
mendations for the utilization of sensitive monitoring
techniques to augment the standard definitions of
posttransplant remission, persistence, progression,
relapse, and the prediction of relapse are proposed,
whenever possible, based on current evidence. It is an-
ticipated that sensitive MRD detection will allow for
earlier therapeutic intervention, and it is hoped that
treatment prior to overt relapse may improve outcome
of alloHSCT for hematologic malignancies. Critically
important is the need to assess the clinical relevance of
MRD surveillance in individual diseases, which in
turn, must be followed by studies to assess the poten-
tial impact of specific interventional strategies. From
the point of view of this Workshop, the use of these pro-
posed definitions and methods should facilitate future
studies of the natural history of relapse (Committee on
Epidemiology and Natural History of Relapse), therapeutic
interventions to prevent clinical relapse (Committee on
Strategies/Therapies Used to Prevent Relapse), and the
treatment of relapse (Committee on Disease-SpecificTreatment of Relapse). Finally, major deficits and
important questions for further clinical research will
be addressed. In this first part, we focus on methods
to detect and monitor disease response, persistence,
progression, and relapse in acute leukemias and myelo-
dysplastic syndrome (MDS), whereas in the forthcom-
ing second part disease-specific monitoring for
chronic leukemias, myeloproliferative neoplasms, and
lymphoid malignancies will be reviewed.METHODS TO DETECTAND MONITOR
DISEASE RESPONSE, PERSISTENCE,
PROGRESSION, AND RELAPSE
A wide variety of techniques are available to mon-
itor residual disease after therapy, including in the
posttransplant setting (Table 1), although the applica-
bility varies by the specific disease subtype and the pre-
dictive value of each method is currently not well
defined for most diseases. Some of these techniques
are difficult to standardize, which is essential to the
conduct of multicenter studies to assess the utility in
the prediction and possible prevention of overt relapse.
Broadly, posttransplant monitoring of disease sta-
tus is assured by 2 different methodologies: specific
MRD detection and characterization of hematopoietic
chimerism. The latter characterizes the origin of post-
transplant hematopoiesis, whereas MRD detection
measures the malignant clone directly. For each ap-
proach, a variety of techniques is available, although
in general there have been more studies looking
directly at markers of residual malignancy than of chi-
merism. Issues of applicability, standardization, sensi-
tivity, and specificity are discussed separately for each
technique.
Chromosome Banding Analysis
Classical chromosome banding analysis still plays
an essential role in the biologic characterization and
for prognostic predictions in many hematologic malig-
nancies. Whenever possible, cultivation of metaphases
is performed from BM instead of peripheral blood
because of the higher proliferation rates and higher
proportions of malignant cells in the setting of leuke-
mia. In vitro proliferation of cells is supported by spe-
cific cytokines. Application of colchicine leads to cell
cycle arrest shortly before metaphase preparation.
Staining of chromosomes is performed with Giemsa-
(G-), Quinacrin (Q-), or reverse (R-) banding tech-
niques. Analysis of metaphases is improved by digital
picture capture systems. The International System of
Cytogenetic Nomenclature (ISCN) is used for the
presentation of karyotypes. Analysis of 20 to 25
metaphases is required for valid results. With chromo-
some banding analysis, the whole karyotype can be
illustrated within a single investigation. However,
Table 1. Diagnostic Methods to Monitor Residual Disease and Relapse of Hematologic Malignancies after alloHSCT
Tumor Marker Chimerism
Method Chromosome
Banding
FISH Flow Cytometry Antigen Receptor
PCR
Translocation or
Other RT-PCR
XY FISH qPCR/STR-PCR
Applicability Subset of
all types
Subset of
all types
ALL; most AML;
CLL; myeloma
ALL; lymphoma;
CLL
CML; subset of ALL;
subset of AML; subset
of lymphoma
Sex mismatched
alloHSCT
All types
with differences in
donor/recipient
polymorphisms
Sensitivity 1021 1022 1023-1024 1024-1025 1023-1026 1022 1023-1026
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leuke-
mia; PCR, polymerase chain reaction; qPCR, quantitative real-time PCR; STR, short tandem repeats.
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sufficient quality of BM samples (eg, myelofibrosis, re-
cent history of total body irradiation [TBI]) as vital
cells are required for metaphase culture. Moreover,
chromosome banding analysis is limited to the detec-
tion of microscopically visible abnormalities. Sensitiv-
ity is further limited, as a maximum of 25 metaphases is
usually evaluated within a single analysis. Further, full
clarification of the chromosomal abnormalities often
requires the combination with molecular cytogenetic
methods using the FISH technique.FISH
Diverse FISH techniques are available for the detec-
tion of submicroscopic alterations or for clarification of
complex chromosomal changes including interphase
FISH (IP-FISH), whole chromosome painting (WCP-
FISH), 24-color-FISH (M-FISH or SKY), and compar-
ative genomic hybridization (CGH). These techniques
are all based on the hybridization of fluorescence-
tagged probes to a specific chromosomal region. WCP-
FISH and 24-color FISH can only be performed on
metaphases. In contrast, FISH with loci specific probes
or with probes for the centromeric regions can be per-
formed on metaphases or interphase nuclei and thus
do not require dividing cells. As interphase-FISH
provides a higher sensitivity (100-200 cells can easily
be evaluated) [4], the technique can be used for MRD
[5], albeit not at a sensitivity approached with other tech-
niques. Moreover, analysis is limited to the probes that
have been chosen for the individual case [6].MFC
The principle of detection of MRD by MFC rests
on the property that leukemic cells have phenotypic
properties that, although broadly similar to those of
normal cells, often show subtle differences in antigen
expression. Considerable effort has been put into
characterizing the patterns of antigen expression in
normal and regenerating hematopoietic differentia-
tion. Comparison of specimens of leukemia to these
normal templates has shown that most cases have
‘‘leukemia-associated immunophenotypes’’ (LAIPs).
Typically, antigens normally expressed at a particularstage of maturation are over- or underexpressed in
leukemic cells. Thus, with design of appropriate com-
binations of antigens in MFC analysis, leukemic cells
can be recognized because they occupy areas of ‘‘empty
space’’ on correlated plots of antigen expression [7-10].
By analyzing large numbers of cells (500,000 or more)
with modern high-speed flow cytometers, it is possible
to identify clusters of as few as 10 to 20 leukemic cells
in a background of normal cells, allowing for a theo-
retic sensitivity approaching 1025 cells. In practice,
however, sensitivities are often limited to about 1024
and may not even reach that in some cases.
Sensitivity of detection of residual leukemic cells
varies between subtypes and depends upon the magni-
tude of the differences seen between leukemic cells and
normal hematopoietic cells. Morever, the proportion
of patients with informative phenotypes varies among
different diseases. Studying larger panels of markers,
either in higher order (more colors) flow cytometry
or by adding additional tubes, will typically increase
the ability to detect MRD. In B-lineage acute lympho-
blastic leukemia (ALL),.90% of patients can be mon-
itored with a relatively simple panel of antibodies
[11,12], and similarly in B-chronic lymphocytic
leukemia (CLL) a simple antibody combination is
informative for detecting MRD at high sensitivity in
nearly all cases [13]. By contrast, MRD detection in
acute myelogenous leukemia (AML) is more compli-
cated because leukemic signatures are often unique
to an individual case, and custom panels are often
designed to monitor particular patients [14-17].
Complicating detection of MRD by flow cytometry
in acute leukemias is the fact that there may be
phenotypic shifts following therapy, so looking only
for those cells with the leukemia specific phenotype
may underestimate, or even fail to identify residual
leukemic cells [18-20]. Therefore, application of
comprehensive antibody panels has been suggested
for follow-up monitoring in AML patients. MRD in
ALL can appear to undergo maturation following ste-
roid therapy, and unless one is aware of this, MRD can
be missed [21]. Phenotypic changes in AML are even
more common, and the complexity of leukemic matu-
rational patterns seen makes it difficult to clearly quan-
tify leukemic populations even when some leukemic
cells are identified. CLL and myeloma are clonal B
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MRD setting, identifying changes in the kappa/
lambda ratio, or using other markers to identify subsets
of cells that express only 1 light chain is generally not
as sensitive as methods that employ the same kinds of
aberrant antigen markers that are useful in MRD
monitoring of acute leukemias [13,22].
Flow cytometric detection of MRD has a number of
advantages over other methods. It is often relatively in-
expensive compared to highly sensitive molecular
methods, and results are obtained rapidly, often within
hours or at most a day or 2, allowing for the design of
studies that have an early therapeutic intervention based
on MRD results. The method is particularly suited not
only to detect, but also to quantify disease burden. This
is of major importance to evaluate disease kinetics. A
major disadvantage to MRD studies by flow in all dis-
eases except CLL and multiple myeloma (MM) is that
no international consensus has been reached on stan-
dardized panel design and data interpretation. Different
panels of antibodies are used by different investigators
and in different studies, and highly specialized experi-
ence is necessary for accurate interpretation of MRD re-
sults. There is even variablility in specimen processing,
with some laboratories using ficolled separated cells [12]
and others using cell lysis techniques [11,23]; some but
not all of the latter techniques express MRD results as
a percentage of mononuclear cells [11] to better match
results obtained with ficolled samples. In contrast to
molecular methods, there are not well-established pro-
tocols for demonstrating interlaboratory reproducibil-
ity. In B-lineage ALL, which is perhaps the best
studied area in this regard, reproducibility is relatively
high early in therapy when MRD burden is high and
when there are the smallest number of contaminating
normal B cell precursors. However, obtaining repro-
ducibility at sensitivities of 1025 or even 1024 is very dif-
ficult [24]. Nevertheless, the clinical importance of
MRD at such a low level has been well established in
a variety of studies performed at 1 or few reference
labs [11,23,25,26], suggesting that it is possible to
measure clinically relevant MRD with that sensitivity.Molecular Methods of Residual Disease
Detection
The polymerase chain reaction (PCR) technique
has proved to be an extremely robust method of high
sensitivity and specificity with a wide range of
applicability to residual disease detection depending
upon the target chosen. PCR can be performed at
the genomic level to look for DNA-based alterations,
or alternatively reverse transcription PCR (RT-PCR)
can be used to detect either structural or quantitative
abnormalities in mRNA. Sensitivity and specificity of
PCR can be improved by using ‘‘nested’’ PCR, in
which a first reaction using primers directed atconsensus sequences is followed by a second reaction
using internal primers to further amplify DNA that
was amplified in the first round. However, this
‘‘nested’’ PCR approach often yields unreliable quanti-
tative results. Finally, PCR can either be performed us-
ing a qualitative or endpoint assay, or, now more
commonly, quantitative real-time PCR (qPCR) can
be used to quantify targets over a range of many orders
of magnitude.Minimal residual disease detection by antigen
receptor PCR in lymphoid malignancies
Approaches for monitoring MRD in B- or T-lym-
phoid malignant diseases comprise techniques based on
PCR to quantify tumor burden by disease-specific T
cell receptor (TCR) or immunoglobulin (Ig) gene
rearrangements [27]. Unique fingerprint-like sequences,
assumed to be specific for each lymphoid cell, can be
detected in the junctional regions of rearranged Ig and
TCR genes. Cells of a lymphoid malignancy have a com-
mon clonal origin, with each cell having an identically
rearranged Ig or TCR gene. Consequently, these gene
rearrangements, located in the junctional regions of Ig
and TCR genes, serve as specific targets for each leuke-
mia and can be used for analysis of MRD [28,29]. At
diagnosis, patient- and leukemia-specific clonal rear-
rangements are amplified by PCR. After this, the various
disease specific rearrangements can be identified and
selected [30]. After selection, PCR products are used
for sequencing of the junctional regions. This specific
sequence forms the basis for the design of junctional
region specific oligonucleotides (allele-specific oligonu-
cleotides [ASO]), required for leukemia, lymphoma, and
myeloma-specific sensitive qPCR-based MRD analysis.
There are a number of potential pitfalls in the use of
Ig and TCR clonality in MRD monitoring. Ig and TCR
gene rearrangements in hematologic malignancies
might be susceptible to subclone formation. Further-
more, secondary gene rearrangements could occur
between diagnosis and relapse, which might cause
false-negative MRD results. To reduce the number of
false-negative MRD analyses in ALL, at least 2 Ig/
TCR targets are used in clinical MRD studies [28,31].
Kreyenberg et al. [32] demonstrated that Ig and TCR
gene rearrangements are stable markers for MRD
in ALL after alloHSCT. Importantly, isolated false
positive results in Ig-based qPCR systems have been
observed at the time of intense B cell regeneration [33].
To assure comparability of MRD results between
different laboratories, quality control and standardiza-
tion are essential. A standardized approach for MRD
analysis by qPCR has been implemented by the Euro-
pean Study Group on MRD detection in ALL (ESG-
MRD-ALL), consisting of 30 laboratories worldwide.
Furthermore, guidelines for the interpretation of
qPCR-based MRD data have been developed.
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pretation of MRD data between different laboratories
of the same MRD-based clinical protocol. Method and
guidelines for its interpretation are precise to avoid
both false-negative and false-positive results [31].
Fusion gene-specific targets and mRNA
expression
Quantitative PCR can be used to monitor specific
fusion gene transcripts as a sensitive indicator of
MRD. Experience is most extensive in the setting of
BCR-ABL1 transcript monitoring for individuals with
CML. The methodology used for identifying BCR-
ABL1 transcripts has evolved over the years. Initially
to BCR-ABL transcripts were detected by single-step
amplification or a 2-step ‘‘nested’’ amplification. In
1993, Cross et al. [34] developed a competitive semi-
quantitative assay that expressed BCR-ABL1 tran-
scripts as a ratio (%) compared with normal ABL
(BCR-ABL1/ABL1  100). This method was adapted
for qPCR when this technology became available
[35,36]. Subsequently Hughes et al. [37], analyzing
patients in the IRIS study, introduced the concept of
logarithmic (log) reduction using as a baseline the
laboratory-specific median BCR-ABL1 transcript level
taken from 30 patients.
For valid PCR data, it is imperative to optimize
each stage of the procedure, including sample collec-
tion, RNA extraction, and quantitative PCR. The
quality of the RNA is extremely important for repro-
ducible data, and consistency in sample collection, tis-
sue type, transportation, and storage conditions will
maximize the accuracy and reliability of analysis. Stan-
dard protocols for BCR-ABL1 PCR employ peripheral
blood for MRD monitoring instead of BM aspirates.
It is highly desirable that a standardized interna-
tional scale for measuring transcript levels be estab-
lished, and it is probably preferable to move away
from log reduction. An international collaborative
group recently published recommendations whereby
the standardized baseline would be determined using
a reference material, and the absolute BCR-ABL1 value
representing a major molecular response would be
standardized at 0.1%. A value of 1.0% would be
approximately equivalent to cytogenetic complete
remission (CR) [38,39].
MRD monitoring by PCR techniques has also been
utilized in the assessment of treatment response and
for the early detection of relapse in other leukemias
with sensitivities of 1024 to 1026 [40-48]. Specific
reciprocal gene rearrangements (eg, PML/RARa,
RUNX1-RUNX1T1 5 AML1-ETO, CBFB-MYH11),
intragenic duplications (eg, MLL-PTD, FLT3-ITD),
and other mutation types (eg, alterations of the
NPM1 gene) can be used for monitoring MRD in
AML [49]. However, reciprocal gene fusions are appli-
cable in a minority of AML patients only. NPM1mutations represent ideal targets for MRD monitoring
by qPCR in adults [50,51], but have a low prevalence in
pediatric AML (8%-10%). Thus, MRD monitoring
based on molecular markers has so far been realized
only for subgroups of patients with AML. In 50% of
patients with myelofibrosis and in 5%-10% of
patients with MDS, the JAK2V617F mutation can be
monitored by sensitive qPCR [52]. Furthermore, the
MPLW515L/K mutation can be detected and moni-
tored in about 5% of myelofibrosis patients [53].
The transcription factor WT1, originally described
as a tumor suppressor gene, is a key molecule for neoplas-
tic proliferation in a large number of hematologic malig-
nancies, making it suitable both as an universal MRD
maker and as a potential target for therapeutic strategies
(eg, vaccination) [45,54-58]. WT1 has been shown to be
expressed in the majority of adult and pediatric cases
of acute leukemias, CML-blast phase, MDS, and both
T- and B-lineage non-Hodgkin lymphoma (NHL),
although the 3-4 log10 overexpression necessary to
make it a reasonable MRD marker is only seen in a subset
of cases [59-65]. The frequency and degree of WT1
expression has been shown to correlate with MDS
disease progression [66]. WT1 expression, quantified
by qPCR, has been evaluated as a marker for risk stratifi-
cation and for MRD detection in AML [44-48,66-69].
However, there are contradictory reports about the
utility of WT1 overexpression to monitor MRD
during frontline chemotherapy and after alloHSCT
[45,46,56,57,70,71].Chimerism
Analysis of chimerism allows monitoring of hema-
topoietic cells from donor and recipient origin after al-
loHSCT to determine engraftment as well as detection
of imminent graft rejection and may also serve as an in-
dicator for recurrence of the underlying malignancy.
Because chimerism analyses were first performed,
many different methods have been developed and im-
plemented, all following the same basic principle using
differences in polymorphic genetic markers and their
products. These methods include cytogenetics [72,73],
red cell, or HLA phenotyping [74-76], restriction
fragment-length polymorphism (RFLP) analysis [77-
80], and FISH of sex chromosomes [81-86]. A major
limitation of these different techniques is that they
are time consuming and not applicable to all patients.
The breakthrough for clinical applicability came
when the PCR technique was developed [87] and also
utilized for investigation of chimerism [88-94].
During the 1990s, these analyses were mainly
performed by the amplification of variable number of
tandem repeats (VNTR) or by the characterization of
short tandem repeat (STR) markers. Fluorescent
labeling of the primers and resolution of PCR
products by capillary electrophoresis allowed accurate
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Semiautomated PCR analyses using the appropriate
hardware permitted a high sample throughput
[93,95-98] facilitiating the study of chimerism in all
patients in short time intervals starting early after
transplantation. Thus, accurate monitoring of
engraftment as well as surveillance of impending graft
rejection and imminent relapse has become possible.
Furthermore, a qPCR assay for the analysis of the
SRY gene on the Y chromosome has been established,
which allows the identification of male DNA in the
background of female DNA at very low levels [99].
This method is able to detect 1 male cell in the back-
ground of 100,000 female cells [100,101] increasing
sensitivity enormously.
Over the past years, qPCR-based chimerism tech-
niques aiming at the amplification of sequence poly-
morphisms (SPs) were established. SPs represent the
most frequent genetic variation, occur on an average
of 1.3 kilobases in the human genome, are mostly bial-
lelic, and differ predominantly only in 1 single nucleo-
tide, denoted by single nucleotide polymorphisms
(SNPs) [102-104]. Alizadeh et al. [105] were the first
to report a set of 11 biallelic polymorphisms using
qPCR amplification for chimerism analysis. The limit
of detection for the minor cell population (0.1%) was
higher than in STR-PCR. This study was followed
by others demonstrating the possibility of accurate
characterization of chimerism by qPCR based on poly-
morphisms [106,107]. In contrast to STR-PCR, where
virtually all recipient/donor pairs could be character-
ized, only 90% of donor/recipients could be discrimi-
nated by this assay. Furthermore, this qPCR technique
showed less quantitative accuracy with a variation
coefficient of 30%-50% for higher autologous signals
[105,106] compared to a variation coefficient of 5%
when applying STR-PCR systems [95,97,108-111].
However, this did not hamper analysis when only
low levels of mixed chimerism were needed to be
quantified. Large prospective trials utilizing this
qPCR method are needed to determine whether the
clinical impact of chimerism analysis can be
improved. For the time being, fluorescence-based
PCR amplification of STR seems to be the gold
standard method for posttransplant chimerism
surveillance and the great majority of the major studies
published to date have used this technique. Despite the
increasing sensitivity of methods to determine chime-
rism, the clinical utility of this approach is limited.
In most hematologic malignancies, chimerism is not
a tumor-specific marker, and finding recipient cells
does not necessarily indicate disease recurrence. The
persistence or reappearance of recipient cells, detected
by molecular methods, could reflect the survival of
leukemic blasts, survival of normal host hematopoiesis,
or a combination of both phenomena. Surviving
host-derived hematopoietic cells could promotereemergence of the malignant clone by inhibiting im-
munocompetent donor- derived effectors.
Hematologic relapse was preceded by reappearing
host-derived hematopoiesis in the mononuclear cell
fraction in CML patients [112]. In consequence, the
graft-versus-leukemia (GVL) effect could be weakend
by a state of mixed chimerism [113]. In several early re-
ports, it remained unclear if a state of mixed chimerism
in patients with an acute leukemia was associated with
an increased risk of relapse. The dynamic process of
the evolution of chimerism was described in the
1990s, and it was concluded that monitoring of chime-
rism should be performed serially and in short intervals
of time. The specificity in this regard is higher in dis-
eases that originate from a stem- or progenitor cell (eg,
CML), in contrast to malignancies that originate from
a later cell stage of development (eg, CLL or mye-
loma), in which case the usefulness of chimerism to
detect MRD or relapse is low. This lack of specificity
might be overcome by performing chimerism on
specific subsets of cells in some diseases (see later)
[114,115]. Here, chimerism is performed on cell
subtypes after isolation by cell sorting or enrichment
(eg, CD138 for myeloma, CD34 for AML and
MDS). Finding chimerism in a population enriched
for tumor cells may increase the likelihood that it is
a true marker of residual disease. Chimerism analysis
may also have value, as it provides information about
the alloreactivity and/or tolerance induction of the
graft and thus may serve as a prognostic factor
independent of its role as a marker for MRD.Imaging
Imaging studies are not generally useful as MRD
markers in leukemias or myeloproliferative neoplasms,
but they play a role in lymphomas and MM. In MM,
lytic lesions are generally diagnosed by radiographic
analysis. One weakness of radiographic detection is
that it may reveal lytic disease only when over 30%
of the trabecular bone is lost [116]. Because of these
limitations, computed tomography (CT) or magnetic
resonance imaging (MRI) have been used to increase
the sensitivity and specificity. CT is currently the
most commonly used means for restaging patients
with lymphoma [117,118]. However, CT lacks
functional information, which impedes identification
of disease in normal-sized organs. 18-F-fluoro-2-de-
oxyglucose (FDG) positron emission tomography
(PET) may be an alternative to CT [119]. MRI is
also utilized for bone and soft tissue reevaluation in
specific situations.
CT
The mainstay of imaging studies for lymphoma has
always been CT scans performed at various intervals.
With current CT scanners, lymph nodes of 5 mm or
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is typically demonstrated on a CT by organomegaly, ab-
normal masses, structural changes, or abnormal contrast
enhancement. One problem with CT scans is that they
have limited specificity, as many different processes can
produce enlarged lymph nodes, even in patients with
lymphoma [120], and a biopsy may be necessary to
confirm residual disease. For use with MM patients,
CT imaging is superior to that of standard radiography
and reveals more lesions compared with conventional
radiology [121].
MRI
MRI has high spatial resolution and excellent soft-
tissue contrast that makes it an ideal tool for the detec-
tion of parenchymal and osseous lesions. However,
because of long imaging time, limited availability,
and extensive costs, MRI was previously used only as
a tool to image limited anatomic areas of the body. Re-
cent improvements in MRI technology have resulted
in the availability of sufficiently fast and diagnostic se-
quences for whole-body (WB) MRI. However, there is
no standard WB-MRI protocol for staging malignant
lymphoma at this time. MRI provides superior soft-
tissue contrast to CT. As with CT, assessment of the
nodal involvement is based on size criteria, and biopsy
is needed for final confirmation of relapse. The MRI
sequences that are most informative for detection of
bone lesions that may be observed in myeloma and
lymphomas, are the T1-weighted, the T1-weighted
with fat suppression and gadolinium contrast, the
T2-weighted with fat suppression, and the short-
time inversion recovery (STIR) images. The STIR
images are particularly sensitive in detecting myeloma-
tous lesions [122].
PET
PET is based on the use of positron-emitting ra-
diopharmaceuticals and the detection in coincidence
of the 2 nearly collinear 511-keV photons emitted
following positron annihilation with an electron. The
increased glycolytic rate of malignant cells is the ratio-
nale behind the common use of FDG as a radiotracer
[123]. More recently FDG-PET and CT scans have
been integrated, which provides both functional and
anatomic information [124]. FDG-PET positivity is
not restricted to malignancy. For example, uptake
can be seen with inflammation and infection resulting
in ‘‘false-positive’’ results in the setting of cancer eval-
uations. FDG-PET scanning has been integrated into
standard staging criteria for lymphomas [125]. FDG-
PET/CT can detect Richter’s transformation of
CLL to diffuse large B cell lymphoma (DLBCL)
with a high sensitivity and a high negative predictive
value [126]. Standardized FDG-PET and PET/CT
imaging procedure guidelines have been published toimprove image quality, reporting, and common imag-
ing standards, and may enable the use of semiquantita-
tive techniques such as the SUV (standardized uptake
value) in assessing response to therapy among centers
worldwide [127]. PERCIST 1.0 is a proposed FDG-
PET/CT response imaging criteria in solid tumors.
This proposes imaging methology and image analysis
to assess response semiquantiatively or quantitatively.
It is intended as a starting point for use FDG-PET
in clinical trials and structured quantitative reporting,
which may be particularly useful when assessing the
activity of newer therapies that stabilize disease
[128]. The standardization of imaging and response
criteria could be a good step in establishing the use
or lack of utility of FDG-PET/CT in early/interim
(after 1-3 cycles of therapy) response monitoring or
early PET response adapted therapy trials [129]. Mul-
tiple novel alternative clinical PET tracers have been
developed, but the greatest experience outside of
FDG-PET has been with 30-deoxy-30-[18F] fluorothy-
midine (FLT), which is an analog for thymidine used
to image tumor proliferation. Early pilot studies using
FLT-PET/CT appear to be very promising in early
response evaluation in lymphoma [130].DISEASE-SPECIFIC DEFINITIONS AND
MONITORING OF RELAPSE AFTER
alloHSCT
Standard diagnostic criteria have been established
to define response and relapse for the hematologic ma-
lignancies. These criteria have historically been based
on morphologic BM investigations (eg, blast count in
acute leukemias), imaging methods (eg, occurrence
of new lymph nodes on FDG-PET scans for NHL),
and/or specific laboratory findings (eg, increased para-
protein by immunofixation and electrophoresis in
MM). Recently, more sensitive methods have been uti-
lized to assess patients for disease response. Some, but
not all of these approaches, have been integrated into
response criteria definitions for various hematologic
malignancies. Herein, we propose criteria for incorpo-
ration of currently available methodologies in the def-
initions for disease response, persistence, progression,
relapse, and the prediction of relapse after alloHSCT.
AML
According to the International Working Group
for Diagnosis, Standardization of Response Criteria,
Treatment Outcomes, and Reporting Standards for
Therapeutic Trials in Acute Myeloid Leukemia, re-
mission criteria in AML are not solely based on mor-
phology, but also include cyto- and molecular
genetic as well as flow cytometric data. Cytomorphol-
ogy and hematologic parameters retain a central posi-
tion (Table 2) [131]. However, very few follow-up
1194 Biol Blood Marrow Transplant 16:1187-1211, 2010N. Kro¨ger et al.studies have been performed to specifically assess these
criteria in the posttransplant period.
These criteria could also be integrated into the as-
sessment of remission in the posttransplant period. Be-
cause of the limited sensitivity of chromosomal
banding [132], interphase FISH seems to be a more
suitable parameter for the assessment of the cytoge-
netic remission status. There are only few studies
that assess the prognostic value of interphase FISH af-
ter AML therapy [5], and even fewer studies addressing
this issue in the posttransplant period. In pediatric
cases with MDS or AML Fuehrer et al. [6] showed
that clonal cytogenetic markers, as assessed by inter-
phase FISH (eg, monosomy 7), reappeared at relapse
after alloHSCT and could be followed after second
transplant. Metaphase FISH proved useful for MRD
diagnostics following standard chemotherapy or al-
loHSCT in an analysis of 22 AML patients performed
by El-Rifai et al. [133], as all but 1 patient with persist-
ing or increasing levels of abnormal cells relapsed.
Chimerism
Both in AML and MDS, several studies demon-
strated the relevance of chimerism, and especially its
kinetics, for the prediction of relapse. Using a semi-
quantive STR method in 81 pediatric alloHSCT re-
cipients with AML, Bader et al. [134] found a relapse
rate of 47% in those with increasing mixed chimerism
(ie, increase of recipient cells) in contrast to 13% in
patients with complete or decreasing mixed chimerism
(P\ .005) [134]. In the study of Huisman et al. [135],
chimerism status was monitored by STR-PCR in T
and non-T cell subsets in 96 patients with AML after
myeloablative (MA) or reduced-intensity conditioning
(RIC). Stable complete donor chimerism was detected
in 56% of patients of the MA group in contrast to 12%
in the RIC group. In samples taken between 1-6
months posttransplant, complete donor chimerism or
decreasing mixed chimerism (ie, decrease of recipient
cells) was significantly associated with a lower relapse
risk (31% versus 83%) and mortality (38% versus
83%, P\ .001) when compared to increasing mixed
chimerism. Similar results were shown by Zeiser
et al. [136], who performed STR-PCR both with
conventional and CD34-specific chimerism methods
in 168 patients with AML or MDS after MAC. With
CD341-specific chimerism, decrease of donor alleles
was detected at a median of 30 days before the clinicalTable 2. Response Criteria in AML According to an International W
Criteria Complete Remission
Morphologic and hematologic BM blasts <5%; thrombocytes $100  109/L; ne
Cytogenetic Disappearance of previous cytogenetic alteration
Molecular Disappearance of molecular mutation
Flow cytometric Disappearance of cells with previously determin
AML indicates acute myeloid leukemia; BM, bone marrow; CR, complete remismanifestation of relapse. The relapse rate was 89% in
patients with mixed chimerism in contrast to 6% in
those with complete donor chimerism.
Molecular genetics
Molecular mutations. A variety of genetic
markers are available for MRD studies and have been
investigated within a standard chemotherapy setting
for their potential to guide therapeutic decisions. In
this setting, MRD measurement is well established
for the reciprocal rearrangements t(15;17)/PML-
RARA, inv(16)/CBFB-MYH11, and t(8;21)/RUNX1-
RUNX1T1. These are found in approximately 20%
of de novo AML cases and confer a favorable prognosis
for patients treated with standard chemotherapy. Ra-
tios of aberrant gene expression after consolidation
therapy and at diagnosis were demonstrated to corre-
late significantly with prognosis [137], and distinct
thresholds of transcript copy numbers were deter-
mined to be associated with an increased relapse risk
[42,41]. After standard chemotherapy, the interval
from the increase of fusion transcripts to
morphological manifestation of relapse was 3-6
months. With respect to the posttransplant period,
Elmaagacli et al. [138] followed 8 patients with
inv(16)/CBFB-MYH11 with reverse transcription
(RT-) PCR. The CBFB-MYH11 transcript was not
detectable in 6 of 7 patients who remained in stable re-
mission post-alloHSCT, whereas relapse occurred in 1
of 2 patients who had been positive 3 months after
alloHSCT.
In patients with de novo AML, the prognostically
favorable nucleophosmin (NPM1) mutations are de-
tectable in approximately 35% of overall AML cases.
In normal karyotype AML, frequencies about 55%
were reported. qPCR or high melting resolution
PCR (‘‘HRM’’) can be used to detect the most frequent
NPM1 mutation subtypes A, B, and D (Figure 1).
Some studies demonstrated a correlation of the muta-
tion load before and after chemotherapy with out-
comes [139-141]. In most studies in the standard
therapeutic setting, NPM1 mutations provided high
stability during follow-up [50,139,140], whereas 1
study described loss of the mutation in 2 of 21
relapsing patients [142]. In an analysis involving 13
stem cell recipients with a history of NPM1 mutated
AML, the achievement of PCR negativity after al-
loHSCT was a precondition for stable remissionorking Group [131]
Relapse
utrophils $1.0  109/L Reappearance of blasts after CR (BM: $5%; PB)
Reappearance of cytogenetic alteration
Reappearance of molecular mutation
ed LAIP Reappearance of cells with LAIP
sion; PB, peripheral blood; LAIP, leukemia associated immunophenotype.
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an increase of the NPM1 mutation level with mean in-
tervals of 24 days (range: 12 - 38 days) in all but 1 case.
The short interval between MRD detection and re-
lapse in NPM1 mutated AML implies that very fre-
quent monitoring (eg, weekly intervals) would be
necessary if this marker were to be used for early ther-
apeutic intervention to prevent hematologic relapse.
The more favorable prognosis of patients with isolated
NPM1 mutations and a normal karyotype suggests that
lower frequencies of this mutation might be expected
in the alloHSCT setting. Posttransplant MRD studies
for this marker would likely be more important in pa-
tients with coincident NPM1 mutations and the prog-
nostically unfavorable internal tandem duplication of
the FLT3 gene (FLT3-ITD) [143,144].
FLT3-ITDs are seen in 20%-25% of all AML
cases and in approximately 40% of cases with normal
karyotypes [145]. FLT3-ITD have variable lengths
and different starting points; thus, qPCR monitoring
requires the design of patient-specific primers [146].
Some studies have indicated that the FLT3-ITD
mutation was unstable, with loss of the mutation in
nearly a fifth of relapsed patients, limiting the validity
of this marker for MRD monitoring [147]. However,Figure 1. Proposed algorithm for follow-up diagnothers have reported instability rates of \5% [148].
Integration of FLT3-ITD in posttransplantation mon-
itoring has been suggested [149], but is still controver-
sial because of the potential for instability of the
mutation [150]. Consequently, a combination with
a second MRD strategy (eg, NPM1 mutations
[49,151]), or with MFC, might be recommended for
FLT3 mutated AML.
Mutations of the tyrosine kinase domain of the
FLT3 gene (FLT3-TKD) are less frequent than the
FLT3-ITD in AML. They occur in 6%-8% of all
AML cases with normal karyotypes [152-156]. The
impact on prognosis remains incompletely defined
[157,156]. Scholl et al. [146] demonstrated that quan-
titative assessment during follow-up with qPCR is fea-
sible as the FLT3-TKD mutations are represented by
single nucleotide base exchanges. Quantitative
follow-up of the FLT3-ITD and the FLT3-TKD was
performed with qPCR in 4 stem cell recipients with
a history of FLT3 mutated AML and showed a signifi-
cant association of relapse to posttransplant PCR pos-
itivity, whereas disease-free survival (DFS) was
associated with attainment of PCR negativity [157].
Partial tandem duplications of the MLL gene
(MLL-PTD) represent another promising marker forostics in the posttransplant period in AML.
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cally unfavorable gain-of-function mutations [158]
occur in 5%-10% of patients with a normal karyotype
[159-162]. MRD studies with qPCR demonstrated
that the amount of reduction of mutated cells was
prognostically relevant in the standard therapeutic
setting. Molecular relapse preceded clinical manifes-
tations by several weeks [163]. To date, no study has
been performed with this marker specifically in the
posttransplant period.
Single gene expression. Monitoring of the ex-
pression of the WT1 gene represents another option
for posttransplant MRD detection in patients with
AML [46,150]. Using qPCR in patients with AML,
ALL, or advanced phases of CML, Ogawa et al. [164]
were able to determine thresholds above which relapse
was predictable within 40 days after alloHSCT. There
was a 100% relapse probability at an expression level of
1-5  1022, whereas the relapse risk was\1% with ex-
pression levels \4  1024. Relapsed patients who
responded to adoptive immunotherapy by donor lym-
phocyte infusion (DLI) or withdrawal of immunosup-
pression showed a significantly longer doubling time
of WT1 expression compared to patients who were
refractory to these approaches. Doubling time of
WT1 transcripts \13 days was predictive for failure
of treatment. Candoni et al. [165] described full concor-
dance between WT1 expression levels and the remis-
sion status of AML before and after alloHSCT.
Jacobsohn et al. [166] evaluated the prognostic signifi-
cance of pretransplant WT1 gene expression as
a marker of MRD in 36 pediatric patients with AML.
Elevated WT1 gene expression before alloHSCT was
predictive of posttransplant relapse and lower 5-year
event-free survival (EFS). After alloHSCT, 76% of
patients with high pretransplant WT1 expression
relapsed, in contrast none of those with low WT1
expression.
Multicenter studies have been initiated to develop
standardization of WT1 measurement (eg, by qRT-
PCR normalized to the ABL gene) [58]. However, the
physiologic background expression of WT1 in healthy
individuals has to be considered. Barragan et al. [141]
compared WT1 expression and monitoring of the
NPM1 mutation load in 24 AML patients and found
a strong correlation between both markers (P\ .001),
but with different disappearance kinetics. WT1 expres-
sion showed rapid decrease after induction therapy, but
residual levels were maintained during CR, whereas
NPM1 mutations showed a mild reduction after induc-
tion, but they were undetectable in long-term survivors.
Thus, assessment by qPCR of theNPM1mutation load
was superior to the assay for WT1 quantification be-
cause of the specificity for leukemic cells and higher
levels of expression at presentation.
Expression of other genes such as BAALC (brain
and acute leukemia, cytoplasmic) [167] might beinvestigated for posttransplant monitoring in normal
karyotype AML as well, although to date there are no
data on their usefulness for this specific purpose.
Thus, a variety of additional genetic markers should
be investigated for their potential utility after al-
loHSCT, particularly those with an adverse impact on
prognosis as they are likely to be overrepresented in
the transplant setting. Efforts should continue to
develop algorithms for monitoring patients with AML
in the posttransplant period (Figure 1).
MFC
The value of immunophenotyping by MFC for the
determination of the remission status in AML has been
confirmed in many studies in the setting of standard
therapy [131]. The decrease of cells with the specific
LAIP from diagnosis to the end of induction therapy
showed significant correlation with the remission rates
and long-term prognosis [168-170], and the reduction
of aberrant cells to a threshold of \0.1% after
chemotherapy was associated with improved survival
rates [171]. Only very few studies [172] have addressed
the value of MFC specifically in the posttransplanta-
tion period, but it was shown that MFC was able to dis-
criminate leukemic cells from regeneration blasts after
alloHSCT [173]. In an individual patient with AML,
withdrawal of immunosuppression was guided by the
results of MFC, as there was an increase of cells with
the LAIP 2 months posttransplant. This was followed
by a subsequent reduction of aberrant cells [174].
Perez-Simon et al. [175] performed MFC in 13 patients
with AML or MDS who had received RIC-alloHSCT.
Persistence of cells with the LAIP within 21-56 days
posttransplant was associated with a relapse risk close
to 60%, whereas all patients with a negative MRD sta-
tus in this period achieved stable remission. Diez-
Campelo et al. [176] performed MRD monitoring by
MFC in 41 alloHSCT recipients with AML or MDS.
A cutoff level of 1023 malignant cells at 100 days post-
transplant was able to discriminate different risk popu-
lations. The 4-year overall survival was 73% in patients
with a low MRD level versus 25% among patients with
high MRD level at this time point, and EFS after 4 years
was 74% versus 17% (P 5 .01) for the same 2 groups.
The authors thus proposed that MRD monitoring
with MFC has relevance for the therapeutic decisions
in the early posttransplant period.
It should be emphasized that 1 advantage of MFC
is the option to perform this technique in AML pa-
tients without evidence of a specific genetic marker.
However, the frequency of changes of the LAIP in pa-
tients relapsing after alloHSCT is unknown, whereas
relapse after standard therapy was associated with
loss of the previous LAIP in approximately 25% of
cases [177]. Thus, further evaluation is needed to
evaluate the status of MFC for AML patients in the
posttransplant period.
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As in AML, standard criteria for the assessment of
remission in MDS have been developed and revised by
an international committee [178]. These new criteria
integrate clinical, morphologic, cytogenetic, and he-
matologic parameters (Table 3). Few studies have eval-
uated MRD diagnostics in patients with MDS in the
posttransplant period.
Molecular Markers
WT1 expression was shown to increase during leu-
kemic transformation of MDS and to decrease follow-
ing chemotherapy or alloHSCT [66]. In a study from
Cilloni et al. [57] that included 131 patients with
MDS, 65% of BM and 78% of PB samples from pa-
tients with refractory anemia (RA) showed WT1 over-
expression, whereas 100% of samples from patients
with either refractory anemia with excess blasts
(RAEB) or secondary AML (sAML) samplesWT1 tran-
script amounts greater than the level observed in
healthy volunteers. Thus, there was significant correla-
tion between the WT1 expression level and the IPSS
score. Similar results were reported by Patmasiriwat
et al. [179], who described increased WT1 levels in ad-
vanced MDS cases, but not in RA. Bader et al. [69]
found significantly higher mean WT1 expression levels
in pediatric patients with RAEB and juvenile myelomo-
nocytic leukemia (JMML) when compared to expres-
sion levels of healthy donors (P \ .001). However,
single samples showed overlap between patients and
healthy individuals.
Tamura et al. [180] reported on a patient of 14
years of age who had a diagnosis of RAEB with an in-
crease of WT1 expression to 16,000 copies/mg RNA in
peripheral blood after alloHSCT. Withdrawal of
immunosuppression was followed by transient and
self-limiting skin graft-versus-host disease (GVHD)
and gradual decrease of WT1 expression during the
next months. Sixteen months after alloHSCT, the
patient was in CR, whereas WT1 expression was below
the detection level. However, because it is difficult to
differentiate clearly between phyisological and aber-Table 3. Revised Criteria for Assessment of Remission in
MDS According to an International Working Group [180]
Criteria Response
Morphologic
and hematologic
Complete remission (CR): bone marrow blasts <5%
without dysplasia, hemoglobin$11 g/dL, platelets
$100  109/L, neutrophils $1.5  109/L.
Partial remission (PR): reduction of blasts by at least
50% or achievement of lower risk category than
prior to treatment.
Cytogenetic Major cytogenetic response: disappearance of
a cytogenetic abnormality.
Minor cytogenetic response: $50% reduction of
abnormal metaphases.
MDS indicates myelodysplastic syndrome.rant gene expression, the usefulness ofWT1 expression
for posttransplant monitoring of myeloid malignancies
remains controversial.
Only a few studies have investigated molecular
mutations in MDS. Most frequent are intragenic mu-
tations of the RUNX1/AML1 gene [181,182]. FLT3-
ITD occurs in 3%-5% of MDS patients [183,185].
Mutations of the NRAS protooncogene were
identified in 6%-10% of all MDS cases. In contrast
to AML, NPM1 mutations are rarely if ever seen in
MDS [186]. Thus, the proportion of MDS patients
who can be characterized with molecular markers is
lower than in AML. However, as FLT3-ITD or
NRAS mutations were demonstrated to increase dur-
ing leukemic transformation [184,185], the selection
of high-risk MDS cases for alloHSCT might be asso-
ciated with an overrepresentation of these markers
when compared to standard therapy cohorts. So far,
no study has specifically determined the frequency of
these molecular markers in the allo-transplant setting.
MFC
Several studies have demonstrated that MFC has
potential diagnostic utility in MDS. Frequently, the
side-scatter (SSC) signal is reduced because of lower
granularity of granulocytes. Aberrant expression pat-
terns of CD13 and CD16 on granulocytes or lack of
CD71 on erythrocytes can also be characteristic
[187,188]. The progression of MDS to higher stages
was shown to be accompanied by an increase in the
flow cytometric scores [189], which correlated with
the International Prognostic Scoring System and prog-
nosis [190]. At this time, no flow cytometric study has
been performed specifically in the posttransplant period
in MDS patients. Whether the frequent finding of bone
marrow dysplasia in the posttransplant period will be an
obstacle for this approach, remains to be clarified.
In conclusion, considering that molecular MRDs
markers are available or under development for specific
AML subgroups only, and the lack of MRD markers in
most MDS patients, surveillance of chimerism repre-
sents the most broadly applicable molecular tool in pa-
tients with these disorders. Monitoring of the kinetics
of chimerism in short intervals is clearly superior to
the interpretation of a single measurement. In addition,
the potential of CD341 specific chimerism for myeloid
disorders seems worthy of further evaluation.
ALL
Standard definitions for response and relapse are
based on clinicopathologic evaluation of peripheral
blood, BM, cerebrospinal fluid, and potential extrame-
dullary sites of involvement. Response criteria rely
most commonly on blood, marrow, and cerebral spinal
fluid (CSF) cell counts and morphology (Table 4).
From the standpoint of long-term outcome, CR has
Table 4a. Response Criteria in ALL
Complete remission (CR): a CR requires that all of the following be recorded concurrently:
 <5% marrow leukemia blast cells (M1).
 No circulating blasts.
 Absolute neutrophil count (neutrophils and bands) $1.0  109/L.
 Platelet count $100  109/L.
 Adequate bone marrow cellularity with trilineage hematopoiesis.
 Absence of extramedullary manifestations of disease (eg, CNS1).
 No evidence of recurrence of ALL for at least 4 weeks.
*Morphologic CR with incomplete blood count recovery (CRi): above CR criteria without specified blood counts.
Cytogenetic CR (CRc): in addition to above CR criteria, reversion to normal karyotype for those with previously detected cytogenetic abnormality.
Molecular CR (CRm): in addition to above CRc criteria, normalization of previously detected molecular cytogenetic abnormality.
*Partial response (PR): requires that all of the following be recorded concurrently:
 Decrease in the percentage of marrow blasts, absolute peripheral blast count, and extramedullary disease by at least 50%.
 #25% marrow leukemia blast cells.
 Absolute neutrophil count (neutrophils and bands) $1.0  109/L.
 Platelet count $100  109/L.
*Stable disease (SD)
 Criteria not met for CR, PR, or progression.
Progressive disease
 An increase of at least 25% in the absolute number of circulating or bone marrow leukemic blasts or extramedullary disease burden; or
 Development of new extramedullary disease.
Relapsed disease
 The reappearance of leukemia blast cells in the blood or the bone marrow ($25%) or in any other extramedullary site after a CR with confirmation of
lymphoid blasts by morphology and flow cytometry, PCR for antigen receptor loci or fusion genes, or cytogenetics/FISH; or
 Increase to >25% blasts in the marrow after a PR.
 Importantly, isolated extramedullary relapses (eg, CNS) are considered relapse from a diagnostic standpoint, although these are commonly approached
differently in terms of therapy.
CNS indicates central nervous system; ALL, acute lymphoblastic leukemia.
*Additional definitions sometimes employed in the context of clinical trial.
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and endpoint. However, criteria for CR with incom-
plete blood count recovery (CRi), partial response,
and stable disease are sometimes utilized in the context
of early phase clinical trials (Table 4).
Importantly, the standard definition for relapse in
patients with CR1 (.25% BM blasts) is insensitive
for use after allogeneic haemaotopoietic stem cell
transplantation, as detailed later.Prognostic Significance of MRD in
Nontransplant Studies
Multiple studies support the independent prognos-
tic value of MRD measurements in pediatric and adult
patients with B- and T-lineage ALL [11,191-219]. It
has been well demonstrated that MRD positivity
(MFC and PCR-based molecular methods) after
induction and consolidation [201,202,204] correlates
with the risk of relapse. Most studies have employed
BM and, in general, this is the preferred sample
source; however, in T-ALL, in contrast to B-ALL,
levels of MRD in blood and marrow correlate closely
so that PB may be utilized in MRD detection
[208,209]. However, measurement in PB may also
provide useful prognostic information in B-ALL
[208], especially early in therapy during periods of
BM aplasia (ie, day 8) [11]. Furthermore, the risk of
relapse appears to be proportional to the level of
MRD, which in some studies was found to be the
most powerful prognostic factor for relapse in
multivariate analyses [26,191-195,203,206,210]. Thekinetics of the decrease in MRD level has been shown
to be more predictive than MRD analyzed at 1 time
point [26,194]. Consequently, MRD detection has
been utilized in the stratification for several ALL
treatment protocols [196,197,206] and to evaluate the
effectiveness of alloHSCT or alternative treatment
approaches [194].Prognostic Significance of MRD at the Time of
Transplant
Pediatric studies
Numerous studies have shown on a retrospective
basis that the MRD status prior to conditioning was
the strongest predictor for posttransplant relapse
[211,212,213]. A British pediatric study in Bristol
reported that an MRD load of greater than 1023
pretransplant was associated with poor survival. In
contrast, a portion of patients with low level disease
burden (\1023) revealed a more favorable outcome,
and MRD-negative children had the best chance of
survival [210].
A retrospective study in Germany including 45
children reconfirmed these results, applying the same
semiquantitative PCR approach. Those patients, en-
tering transplantation with high-level MRD (.1023)
were rarely cured. Interestingly, residual disease could
be eradicated by posttransplant immunotherapy in
some of these high-risk patients [206].
Recently Bader et al. [214] published prospective
data on MRD analysis in 91 children with relapsed
Table 4b. Bone Marrow Classification
Blast Percentage (at least 200 nucleated cells counted)
M1 <5%
M2 5%-25%
M3 >25%
Bone Marrow Classification in ALL.
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within the ALL-REZ BFM Study Group. The proba-
bility of EFS and cumulative incidence of relapse
(CIR) in patients with MRD $1024 were 0.27 and
0.57, respectively, compared to 0.60 and 0.13 in 46
patients with MRD \1024 (EFS: P 5 .004; CIR:
P \ .001). Multivariate Cox regression analysis
revealed MRD as the only independent parameter
predictive for EFS. These findings proved the clinical
significance of MRD analysis prior to alloHSCT as
a predictor for posttransplant outcome in a large
prospective study. Based on this, new strategies with
modified alloHSCT procedures will be evaluated
within the ALL-BFM trials.
Adult studies
There are few studies examining the prognostic sig-
nificance of MRD detection prior to and following al-
loHSCT for adults with standard risk B-cell ALL. In
several older studies [198-201], semiquantitative PCR
analysis failed to detect a strong association of MRD
in CR1 prior to alloHSCT with posttransplant DFS.
In 1 of these studies [201], there was no significant dif-
ference in pretransplant MRD detection for the 14 pa-
tients who were in continuous CR after transplant; 8
were MRD positive and 6 were MRD negative prior
to alloHSCT. However, there was an association with
pretransplant MRD and risk of relapse for a cohort of
patients who underwent autologous HSCT in CR.
Twenty-one of 23 patients (91%) who were MRD-
negative prior to autologous HSCT remained in long-
term remission following transplant. In contrast, 6 of
7 patients (86%) who tested MRD-positive prior to au-
tologous HSCT relapsed following the transplant (P5
.005). In this same study, posttransplant MRD detection
was strongly associated with relapse-free survival (RFS)
for the 19 patients undergoing alloHSCT. There were
no relapses in patients who remained MRD-negative
following alloHSCT, whereas both patients with de-
tectable MRD following transplant relapsed.Table 4c. Central Nervous System (CNS) Classification
Cerebrospinal Fluid Cell Count and Cytology
CNS1 Absence of blasts on cytospin preparation.
CNS2 <5 white blood cells/mL and cytospin positive for blasts.
CNS3 $5 white blood cells/mL and cytospin positive for blasts.
Bone Marrow Classification in ALL.A more recent study using qPCR examined the
clinical impact of MRD detection in 43 adults with
high-risk ALL who underwent alloHSCT [215]. The
group was heterogeneous in regard to disease subtype
and status, conditioning, and donor type. Overall
survival (OS) at 36 months was 48%. For patients
who were PCR-negative prior to transplant, 80%
were alive at 36 months in contrast to 49% survival
for PCR-positive patients (P 5 .17). For the same
patients, the cumulative incidence of relapse was 0%
for PCR-negative and 46% for PCR-positive patients
(P 5 .03). The relapse rate calculated according to
the molecular results at 100 days following alloHSCT
confirmed that the achievement or maintenance of
a PCR-negative status within 3 months following
transplantation was significantly associated with
a lower incidence of relapse at 36 months posttrans-
plant (7% versus 80%, P 5 .0006). In a multivariate
analysis to investigate the role of clinical findings
including disease status prior to transplant, cytogenet-
ics, immunophenotype, age, and pretransplant MRD
level, only molecular CR before conditioning proved
to be a significant predictor of the achievement of
MRD negativity at 100 days after transplantation.
Bassan et al. [206] recently demonstrated the utility
of risk-adapted therapy based on MRD measurements
for adults with ALL. MRD measurements taken at
weeks 10, 16, and 22 of therapy using qPCR were
used to stratify treatment for adults receiving intensive
postremission chemotherapy for ALL in CR1. Of 280
patients registered to the trial, 112 were evaluable for
MRD at the end of consolidation therapy. Of these,
58 had no measurable MRD and 54 were MRD-
positive. Five-year OS was 75%, and DFS was 72%
for the MRD-negative group in comparison with
33% OS and 14% DFS (P 5 .001) for the MRD-
positive group (regardless of pretreatment risk assign-
ment based on clinical, immunophenotypic, and
cytogenetic features). They further stratified postre-
mission treatment based on MRD. Those patients
who were MRD-positive at weeks 16 through 22
were assigned to receive alloHSCT in CR1 if an avail-
able donor was identified, or in the absence of a donor,
to an intensification of postremission chemotherapy.
Those who were MRD-negative went on to receive
traditional maintenance therapy. Thirty-six of 54
(67%) MRD-positive cases proceeded to alloHSCT
or to the intensified chemotherapy phase. There was
a clear improvement in 4-year DFS for these 36 pa-
tients estimated at 33% in comparison to no survivors
among the 18 MRD-positive patients who did not re-
ceive either intensified treatment approach. Notably,
MRD status after the intensified treatment further de-
fined prognosis for this group. For the patients who
achieved a MRD-negative state following alloHSCT
or intensified chemotherapy, the DFS was 51%; for
those who were remained MRD-positive, there were
Table 5. Published Studies on the Use of Chimerism and MRD in alloHSCT for ALL
Chimerism
Late 1980s to mid 1990s
Author Patients (n)
Graft
(n)
T Cell
Depleted Interval of Investigations Methods
State of Chimerism Relapses
MC CC MC CC
Schattenberg et al.,
Blood 1989 [74]
29 29 yes 6, 12 months Red cell phenotype
Cytogenetics
RFLP
19/29 3/19
Van Leeuwen et al.
Blood 1993 [245]
53 46
7
yes
no
2, 6, 12 months VNTR 23/53 30/53 8/23 10/30
Roy et al.
Blood 1990 [246]
43 43 yes 0.5, 1, 3, 6, 9,
12, 18, 24 months
RFLP 22/43 21/43 11/22 6/21
Lawler et al.
Blood 1991 [89]
32 12
20
yes
no
not given VNTR and STR 10/12
8/20
2/12
12/20
4/10
2/8
0/2
0/12
Bader et al.
BMT 1998 [247]
55 55 no Weekly VNTR and STR 18/36
1 autologous recovery
Increasing MC: relapse
Chimerism with Intervention
2003 to 2008
Author Patients (n) Diagnosis Interval of Investigations Methods Relapses
Formankova et al.
Haematologica 2003 [229]
54 ALL, AML, CML,
and MDS
Children
weekly to +100;
monthly
STR MC associated with
rejection and relapse,
immunotherapy was
possible
Gorczyn˜ska et al.
BMT 2004 [230]
14 ALL, AML
Children
weekly to +100;
monthly
STR Increasing MC could be
converted by
immunotherapy to CC
Bader et al.
JCO 2004 [235]
163 ALL
Children
weekly to +100;
monthly
STR MC associated with
rejection and relapse,
immunotherapy was
possible
Horn et al.
BMT 2008 [248]
20 ALL, AML
Children
1, 3, 6, 12 months;
in MC bi-weekly
STR MC associated with relapse,
immunotherapy was not
possible
Pretransplant MRD
Retrospective Studies
Author Patients (n) Diagnosis Interval of Investigations Methods
Survival According
to MRD Status
Knechtli et al.
Blood 1998 [213]
64 ALL prior to conditioning Ig/TCR PCR high level positive—0%
low level positive—36%
negative—73%
Bader et al.
Leukemia 2002 [211]
41 ALL prior to conditioning Ig/TCR PCR high level positive—23%
low level poitive—48%
negative—78%
Uzunel et al.
Blood 2001 [249]
30 ALL prior to conditioning Ig/TCR PCR high level positive—47%
low level positive—50%
negative—100%
Sramkova et al.
Ped Blood Cancer 2007
[250]
25 ALL prior to conditioning Ig/TCR PCR positive—0%
negative—94%
Prospective Studies
Bader et al.
JCO 2009 [214]
91 ALL prior to conditioning Ig/TCR PCR MRD $1024:
EFS 27%; CIR 57%
MRD <1024:
EFS 60%; CIR 13%
Posttransplant MRD
Retrospective Studies
Knechtli et al.
BJH 1998 [237]
68 ALL up to 24 months
posttransplant
Ig/TCR PCR relapse—88% positive
remission—22% positive
Uzunel et al.
BJH 2003 [239]
23 ALL 24 months Ig/TCR PCR MRD positive
associated with
relapse
Sanchez et al.
BJH 2002 [238]
40 ALL day 30, 60, 90,
every 2 to 3 months
Flow cytometry positive—33%
negative—74%
(Continued)
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Table 5. (Continued )
Pretransplant MRD
Prospective Studies
Author Patients (n) Diagnosis Interval of Investigations Methods
Survival According
to MRD Status
Bader et al.
BMT 2009 [240]
92 ALL day 30, 60, 100,
200, 365 posttransplant
Ig/TCR PCR MRD $1024:
EFS 9%; RFS 11%
MRD <1024:
EFS 48%; RFS 62%
Mortuza et al.
JCO 2002 [201]
19 ALL
(B-lineage)
1 to 20 months Ig/TCR PCR
(semiquant.)
positive – 0%
negative – 100%
Spinelli et al.
Haematologica
2007 [215]
37 ALL day 100 Ig/TCR or fusion
gene PCR
(quantitative)
positive >1024—20%
negative—93%
Bassan et al.
Blood 2009 [206]
18 ALL
(All patients were PCR
positive prior to
transplant)
not defined Ig/TCR PCR positive >1024 —0%
negative—50%
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CIR, cumulative incidence of relapse; CC, complete chimerism; CML,
chronic myelogenous leukemia; EFS, event-free survival; Ig, immunoglobulin; MC, mixed chimerism; MDS, myelodysplastic syndromes; PCR, polymerase
chain reaction; RFLP, restriction fragment length polymorphism; RFS, relapse-free survival; STR, short tandem repeats; TCR, T cell receptor; VNTR,
variable number tandem repeats.
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that allocation to standard maintenance therapy for
patients with MRD-negative status following consoli-
dation results in excellent DFS and that intensification
therapy with alloHSCT or repeated cycles of intensifi-
cation chemotherapy can salvage some very high-risk
patients (MRD-positive at the end of consolidation)
who would otherwise relapse with near certainty.Pretransplant MRD monitoring in Philadelphia
chromosome-positive ALL
MRD detection prior to transplant for Philadel-
phia chromosome positive (Ph1) ALL is a good
predictor of RFS after transplant [216-220]. The
addition of targeted tyrosine kinase inhibition with
imatinib to frontline therapy of Ph1 ALL has
resulted in the ability to significantly reduce or
eradicate MRD during the first months of treatment
using sensitive qRT-PCR assays [221-224]. A
number of recent studies have demonstrated that
achievement of a molecular CR as assessed by qPCR
immediately prior to the time of transplant correlates
with improved DFS and OS after alloHSCT. In 1 of
the larger studies, when imatinib was added to front-
line therapy, 82% of the patients became PCR nega-
tive and the majority was able to proceed to transplant
[225]. With a median follow-up of 25 months follow-
ing transplant, outcome of these patients appeared to
be improved with a DFS of 78% in comparison to
studies in the preimatinib era where DFS following al-
loHSCT for adults with Ph1 ALL was in the 30% to
50% range. The kinetics of MRD eradication prior to
alloHSCT may also be an important prognostic fea-
ture. Lee et al. [226] studied MRD in 41 patients
with Ph1 ALL who were treated with combinationchemotherapy induction followed by 4 weeks of imati-
nib therapy. They found that 36 of 41 patients
achieved at least a 3-log reduction of MRD following
the first 4 weeks of treatment with imatinib. This early
reduction in MRD was identified as the most powerful
predictor of lower relapse rate following alloHSCT.
For patients with at least a 3-log reduction in MRD,
the relapse rate following alloHSCT was 12% in com-
parison to the other patients who had a relapse rate of
45% (P5 .011) [227]. These data, similar to the pedi-
atric data presented before, suggest that pretransplant
MRD detection in adults with ALL may be an impor-
tant guide to early posttransplant treatment to attempt
to avert clinical relapse.Role of MRD Monitoring and Chimerism
Assessment following alloHSCT for ALL
Pediatric and adult studies (Table 5)
Assessment of chimerism using the semiquantita-
tive STR-PCR approach, which analyzed microsatel-
lite regions, has demonstrated that ALL patients
with rapid increase of mixed chimerism were at the
highest risk of relapse post-alloHSCT [113,228-231].
The analysis of cell subpopulations in acute leukemia
patients revealed a potential difference between
children and adults. Guimond et al. [232] demon-
strated that mixed chimerism in T and natural killer
(NK) cells was frequently detected in children with
relapsed leukemia but not in pediatric patients, who re-
mained in remission. Furthermore this phenomenon
was not observed in relapsed adult patients.
The clinical relevance of a state of increasing mixed
chimerism as a risk factor for relapse in patients with
acute leukemia was demonstrated by Barrios et al. in
1202 Biol Blood Marrow Transplant 16:1187-1211, 2010N. Kro¨ger et al.2003 [233]. However, a group in Germany showed
a more complicated relationship between chimerism
and relapse [234]. They showed that the persistence
of mixed chimerism in the early-phase posttransplant
as predominantly caused by normal recipient-derived
hematopoiesis. The reappearance of leukemic blasts
was preceded by an increase of this recipient-derived
normal hematopoiesis, denoted by increasing recipient
chimerism. These results promoted the hypothesis that
mixed chimerism weakened the clinical GVL effect,
which was thought to be mediated by donor-derived al-
loreactive effectors in acute leukemia patients. These
results formed the basis for several clinical trials to
study the efficacy of relapse prevention by preemptive
immunotherapeutic intervention based on the analysis
of chimerism in acute leukemia patients [229,230].
By applying STR-based analysis of chimerism at
defined regular intervals posttransplant, in 2004, Bader
et al. [235] defined a subset of children with impending
relapse, applying STR-based analysis of chimerism at
defined regular intervals posttransplant. Beyond that,
prevention of overt relapse was possible in a portion
of patients by preemptive immunotherapeutic inter-
vention (withdrawal of immunosuppression or admin-
istration of DLI), although impending relapse was not
diagnosed in all patients because of the short time in-
terval between the conversion of chimerism and the
occurrence of relapse in some patients.
Importantly, analysis of chimerism by conven-
tional STR-PCR does not incorporate the potential
to detect MRD because of its limited sensitivity
(approximately 1%). Thus, the decision to start immu-
notherapy should not be based exclusively on the state
of chimerism, because this might result in a delay of
onset of beneficial interventional therapy.
A German retrospective analysis including patients
who had received DLI based on a state of increasing
mixed chimerism also measured the MRD burden,
applying qPCR (Ig/TCR rearrangements). It was
demonstrated that those patients with an MRD burden
of .1023 did not benefit from interventional therapy,
whereas patients with an MRD load\1023 at initia-
tion of immunotherapy showed a survival rate just
below 40% at 2 years [236].
The significance of MRD analysis posttransplant
has only been investigated in a few prospective studies.
In 1998, Knechtli et al. [237] showed that persistent
MRD positivity represented an unfavorable predictor
for EFS. Here, MRD was assessed by a semiquantitative
dot blot hypridization approach. These initial results
could be confirmed later in a smaller cohort of patients
by immunophenotyping of antigens associated with
leukemia [238] and by molecular qPCR based ap-
proaches [175,215,239]. These trials all showed MRD
to be a predictor for poor posttransplant outcome.
Recently, the ALL-REZ BFM Study Group moni-
tored MRD in 92 pediatric ALL patients after alloHSCTto highlight patients with highest risk for relapse to whom
preemptive treatment might be offered. The probability
of EFS and RFS for MRD-negative patients was 0.55 and
0.77, respectively, compared to 0.48 and 0.62 in MRD-
positive patients with\1024 and compared to 0.09 and
0.11 in MRD-positive patients with$1024, respectively
(EFS: P\ .005; RFS: P\ .001). Patients who remained
persistently MRD-negative showed a RFS of 0.78 com-
pared to 0.5 in patients who became MRD-negative,
and compared to only 0.1 in patients who developed an
increase of MRD $1024 and of 0 in patients with
MRD levels remaining permanently .1024 (P\ .001).
Consequently, patients with reappearing or persisting
MRD load at a level of$1024 faced the highest risk for
subsequent relapse and may therefore be candidates for
further interventional therapy [240].
MRD by molecular Ig/TCR rearrangements is im-
possible in patients lacking a disease-specific marker.
In these cases, the status of chimerism can be used as
a surrogate marker for MRD if it is analyzed in specific
cell subpopulations. Thiede et al. [241] demonstrated
that a state of mixed chimerism in the CD341 cell frac-
tion predicted relapse in PB in ALL and AML patients.
In 1998, Winiarski et al. [242] characterized chime-
rism in cell subsets, which carried the leukemic pheno-
type. A remarkable correlation between the presence
of MRD and a state of mixed chimerism in the respec-
tive cell subpopulation was detected. However, large
prospective trials proving the predictive value of mixed
chimerism in cell subsets have not been published yet.
Taken together, posttransplant serial monitoring
of chimerism by conventional STR-PCR in PB al-
lowed for the identification of patients with impending
relapse. Therefore, frequent chimerism analyses are
indispensable within the first 200 posttransplant
days, when most relapses occur.
The combination of characterization of chimerism
and analysis of MRD ensures the documentation of en-
graftment and surveillance of posttransplant state of
remission. These approaches provide a rational basis
for individual immunotherapeutic intervention to pre-
vent the recurrence of the underlying malignancy.
However, it should be noted that the clinical impor-
tance of MRD in ALL patients after allogeneic stem
cell transplantation could not be verified in some
studies [210].
Posttransplant MRD monitoring in Ph1 ALL
Beginning in the late 1990s, studies to assess MRD
status following alloHSCT have provided intriguing
information about the risk of relapse in Ph1 ALL
[216-219,243]. First, using qualitative RT-PCR test-
ing with sensitivities reported in the 1025 to 1026
range, a number of studies found that patients who
were consistently PCR negative following alloHSCT
were unlikely to relapse. Conversely, patients in
whom MRD was detected after transplant were at
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Biol Blood Marrow Transplant 16:1187-1211, 2010 1203NCI First International Workshopvery high risk of relapse. In the largest published series,
Radich et al. [218,219] found that the relative risk (RR)
of relapse was significantly higher for patients with
detectable MRD following transplantation than for
those without detectable BCR-ABL1 transcripts (RR:
5.7; P 5 .025). The prognostic significance of the
PCR assay remained after controlling for other
clinical variables (eg, stem cell source, GVHD) that
could influence relapse risk. Interestingly, the genetic
context of MRD may also be of relevance. In this
study, Radich et al. noted that the risk of relapse was
greatest for MRD-positive patients with a p190 BCR-
ABL1 transcript in comparison to patients who had de-
tectable p210 BCR-ABL1 transcripts after transplant.
Use of imatinib after alloHSCT appears to be
useful for eradication of MRD in some patients. Wass-
mann et al. [244] showed that initiation of imatinib for
MRD-positive patients after alloHSCT was associated
with a rapid molecular CR and prolonged DFS in 14 of
27 treated patients. There have also been anecdotal re-
ports of initiation of targeted tyrosine kinase inhibitor
therapy at the time of clinical relapse with reinstitution
of donor chimersim and achievement of prolonged
remission with or without DLI.T
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.Summary and Future Directions: Risk-Adapted
Therapy of ALL Based on MRD
Taken together, all the studies suggest that MRD
measurements in patients with ALL taken in the first
4-20 weeks of postremission therapy have strong prog-
nostic significance and can identify patients with both
a good and poor prognosis. Similarly, detection of pre-
transplant MRD in pediatric and some adult studies is
highly predictive of relapse following alloHSCT and,
coupled with posttransplant MRD evaluation, may guide
early posttransplant intervention such as early with-
drawal of immunosuppression, administration of DLI,
or addition of posttransplant maintenance therapy (eg,
targeted tyrosine kinase inhibiation for Ph1 ALL).
Thus, there are ample data demonstrating that
MRD monitoring is a powerful prognostic tool in pe-
diatric and adult ALL and may be used to risk-adapt
treatment. The introduction of novel treatment strat-
egies to eradicate MRD early during treatment should
be a goal of future trials and may eventually obviate the
need for alloHSCT. Characterization of MRD before
transplantation defines those patients at highest risk
for relapse after alloHSCT. Importantly, although it
appears that MRD detection can facilitate the decision
to advise an allogeneic transplant in CR1, the outcome
for MRD1 positive patients, even with the most ag-
gressive approaches currently available, is still rela-
tively poor. After alloHSCT, MRD measurements
can be used to guide novel therapeutic interventions
and assess their efficacy. MRD monitoring allows the
detection of impending relapse in a substantial
1204 Biol Blood Marrow Transplant 16:1187-1211, 2010N. Kro¨ger et al.percentage of children undergoing transplantation for
ALL. These analyses have recently served as the basis
for treatment intervention to avoid graft rejection,
maintain engraftment, and treat-imminent relapse.SUMMARY, CONCLUSIONS, AND FUTURE
RESEARCH
Because the intention of alloHSCT is to cure the
underlying hematologic malignancy, and because
there is increasing evidence that minimal disease after
alloHSCT may be eradicated by immunotherapeutic
approaches such as DLI, monitoring of disease is of
great importance. The current definitions of remission
and relapse utilized to evaluate most hematologic ma-
lignancies during upfront therapy lack sufficient sensi-
tivity for use after alloHSCT. Flow cytometry,
molecular methods, and new imaging modalities
have been investigated in recent years and can sub-
stiantially increase the sensitivity of disease detection
up to 1024 to 1026. The highest sensitivity and speci-
ficity can be achieved by molecular monitoring of tu-
mor- or patient-specific markers measured by PCR,
but not all diseases have such targets for monitoring.
Similar sensitivity can be achieved by determination
of donor chimerism, but its specificity regarding detec-
tion of relapse is low and differs substantially among
diseases. A higher specificity might be obtained by
lineage-specific donor chimerism, but there are only
a few such studies with limited number of patients.
Critically important is the need for standardization
of the different residual disease techniques. Table 6
summarizes the different methods of MRD detection
in the monitoring of ALL, AML, and MDS, and the
relative pros and cons of use of these methods after
alloHSCT. Further clinical trials to assess the utility
of these techniques in each disease entity are also man-
datory. The predictive value of posttransplant MRD
and chimerism, and the optimal timepoints to assess
kinetic changes in these measurements remains to be
determined across all hematologic malignancies.
Subsequent studies must then be performed to evalu-
ate the efficacy of MRD- and chimerism-guided
therapeutic interventions designed to prevent overt re-
lapse. Thus, critical objectives for future studies in this
area should include the following:
1. Standardize measurement of molecular markers for
each hematologic malignancy for which alloHSCT
is employed.
2. Determine the optimal frequency for monitoring
MRD and chimerism after alloHSCT.
3. Define kinetic changes in MRD and chimerism that
occur after alloHSCT and establish criteria for re-
mission and relapse that incorporate measurement
of these molecular markers in the definition of
response and remission after alloHSCT.4. Assess the efficacy of interventional strategies based
changes in MRD and/or chimerism to prevent
clinical relapse.ACKNOWLEDGMENTS
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